The history of Viagra presents a challenging picture for shareholders. While the initial launch generated significant returns, the end of its intellectual property protection opened the floodgates to off-brand versions, dramatically diminishing sales. This presents a unique dilemma for drug manufacturers relying on comparable blockbuster medication

The history of Viagra, and its creator copyright, presents a complex case study for investors. Originally a blockbuster drug, producing billions in revenue , its patent expiration created a flood of lower-priced alternatives , significantly diminishing its market share . While specific firms may try to capitalize on male sexual dysfunction, the pre